Connect with us


Health News: Pharma exports at risk as Middle East crisis worsens, warns ET HealthWorld



Middle East crisis escalation may hurt pharma exports, Health News, ET HealthWorld

The conflict in the Middle East could potentially impact India’s pharmaceutical exports, industry experts warn. While exports have not yet been affected, the situation remains critical as any escalation in the conflict could have repercussions for the entire Middle East and North Africa (MENA) region, where many Indian pharmaceutical companies have a significant presence.

Companies such as Sun Pharma, Dr Reddy’s, Lupin, Torrent, and Divi’s Labs are among those that could be most affected due to their strong foothold in the MENA region. Sun Pharmaceutical, for instance, has a fully-owned subsidiary, Taro Pharmaceutical, based in Israel, which could face supply chain disruptions.

India supplies bulk drugs, intermediaries, drug formulations, and biologicals to countries in the MENA region, with imports from India to countries like the UAE, Qatar, Saudi Arabia, Egypt, and Bahrain amounting to a billion dollars annually. The region relies on India for a wide range of pharmaceutical products, including anti-infectives, injectables, and therapies.

The tense situation in the Middle East, including recent attacks by Iran on Israel, has raised concerns about potential disruptions in the pharma sector. Operations and supply chain issues in these countries could be affected if tensions continue to escalate, leading to shortages of essential drugs.

With airlines changing routes and shipping companies halting operations in response to the volatile situation, experts fear that delivery times and supply chains could be severely disrupted. The ongoing conflict between Israel and Iran-aligned groups in various countries in the region has only added to the uncertainty surrounding the future of India’s pharmaceutical exports to the MENA region.

Click to comment

You must be logged in to post a comment Login

Leave a Reply